Alpha Tau Medical (NASDAQ:DRTS) Hits New 1-Year High – Time to Buy?

Posted by George Bondi on Aug 27th, 2026

Alpha Tau Medical Ltd. (NASDAQ:DRTS – Get Free Report)’s stock price hit a new 52-week high during trading on Thursday . The stock traded as high as $15.10 and last traded at $15.0340, with a volume of 251547 shares changing hands. The stock had previously closed at $14.96.

Analyst Upgrades and Downgrades

DRTS has been the topic of several analyst reports. Barclays increased their price target on shares of Alpha Tau Medical from $15.00 to $17.00 and gave the stock an “overweight” rating in a research report on Thursday, June 4th. Weiss Ratings restated a “sell (d-)” rating on shares of Alpha Tau Medical in a research note on Friday, July 17th. HC Wainwright raised their target price on Alpha Tau Medical from $15.00 to $16.00 and gave the company a “buy” rating in a report on Tuesday, August 11th. Piper Sandler lifted their price target on Alpha Tau Medical from $5.00 to $8.00 and gave the company a “neutral” rating in a research note on Tuesday, May 19th. Finally, Benchmark reissued a “buy” rating on shares of Alpha Tau Medical in a report on Thursday, July 23rd. Five research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $12.80.

Check Out Our Latest Stock Report on Alpha Tau Medical

Alpha Tau Medical Stock Performance

The firm has a market capitalization of $1.36 billion, a price-to-earnings ratio of -14.48 and a beta of 1.17. The company has a current ratio of 11.09, a quick ratio of 7.79 and a debt-to-equity ratio of 0.15. The stock’s 50-day moving average is $12.74 and its 200-day moving average is $9.79.

Alpha Tau Medical (NASDAQ:DRTS – Get Free Report) last posted its earnings results on Monday, August 10th. The company reported ($0.50) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.36). The business had revenue of $0.10 million for the quarter, compared to analysts’ expectations of $0.14 million. On average, analysts predict that Alpha Tau Medical Ltd. will post -0.92 EPS for the current fiscal year.

Insider Transactions at Alpha Tau Medical

In other Alpha Tau Medical news, CFO Raphi Levy sold 32,500 shares of the stock in a transaction dated Wednesday, June 3rd. The stock was sold at an average price of $10.83, for a total value of $351,975.00. Following the completion of the transaction, the chief financial officer directly owned 147,680 shares in the company, valued at approximately $1,599,374.40. This trade represents a 18.04% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Over the last ninety days, insiders sold 132,871 shares of company stock valued at $1,562,208. 39.50% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Envestnet Asset Management Inc. bought a new stake in Alpha Tau Medical during the 3rd quarter worth approximately $62,000. Bank of America Corp DE raised its stake in shares of Alpha Tau Medical by 2,779.1% during the third quarter. Bank of America Corp DE now owns 22,457 shares of the company’s stock valued at $101,000 after acquiring an additional 21,677 shares during the last quarter. Millennium Management LLC acquired a new position in shares of Alpha Tau Medical during the third quarter worth $170,000. Mariner LLC grew its stake in shares of Alpha Tau Medical by 185.8% in the third quarter. Mariner LLC now owns 123,250 shares of the company’s stock worth $556,000 after purchasing an additional 80,129 shares during the last quarter. Finally, Trifecta Capital Advisors LLC bought a new stake in shares of Alpha Tau Medical in the fourth quarter worth $48,000. Institutional investors own 2.65% of the company’s stock.

Alpha Tau Medical Company Profile

(Get Free Report)

Alpha Tau Medical Ltd. is a medical technology company headquartered in Ness Ziona, Israel, focused on developing targeted alpha-radiation therapies for the treatment of solid tumors. The company’s core innovation, known as Diffusing Alpha-emitters Radiation Therapy (DaRT), employs short-lived radioactive isotopes to deliver high-energy alpha particles directly within or adjacent to tumor tissues. By harnessing the potent cytotoxic effects of alpha radiation, Alpha Tau Medical aims to offer a novel approach to brachytherapy that can potentially overcome radioresistance and spare surrounding healthy tissue.

The company’s lead product, Alpha DaRT, is currently being evaluated in clinical studies for a range of indications including recurrent or metastatic head and neck cancers, skin cancers, and other solid tumors.